30 November 2021: ReNeuron Group plc (AIM: RENE), a UK based leader in Stem Cell and Exosome Technologies, announces its interim results for the six months ended 30 September 2021.
30 November 2021: ReNeuron Group plc (AIM: RENE), a UK based leader in Stem Cell and Exosome Technologies, announces its interim results for the six months ended 30 September 2021.
19 November 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that new data relating to its CTX-derived induced Pluripotent Stem Cell (“CTX-iPSC”) platform has been presented this week, showing their commercial potential for the development of mass-scale therapeutics for peripheral nerve repair.
ReNeuron collaborates with UCL to generate anti-cancer immune cells for cancer therapies
To view the presentation of the preliminary results for the year ended 31 March 2020 please click here.
20 July 2020: ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 March 2020.
17 June 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, provides the following update on its cell-based therapy programmes.